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Slow-reacting substance of anaphylaxis (SRS-A) ~ is an acidic, sulfur-containing chemical 
mediator  with  an  approximate  tool  wt  of  500-600  (1,  2),  which  is  released  during 
immediate hypersensitivity reactions and has the capacity to increase vascular permeabil- 
ity (3)  and to contract certain smooth muscle preparations (4).  The release of SRS-A in 
vitro was initially detected by analysis of the perfusates obtained from sensitized guinea 
pig heart-lung preparations  (5,  6)  and the  diffusates of isolated segments of guinea pig 
lung (7)  challenged with specific antigen. Subsequently,  SRS-A was released in vivo into 
the peritoneal cavity of the hyperimmunized rat by intraperitoneal challenge (8) and into 
the plasma of the sensitized guinea pig undergoing systemic anaphylaxis in response to 
intravenous  antigen  (9).  Studies  with  passively sensitized  guinea  pig  (10) and  primate 
lung  fragments,  monkey  (11) or  human  (12,  13),  demonstrated  that  IgG1  and  IgE, 
respectively, prepared the tissues for subsequent antigen-induced release of SRS-A. More 
recently,  material with the  functional  activity of SRS-A has  been released by antigen 
challenge of sensitized monkey lung suspensions containing  mast cells (14)  and human 
leukocyte preparations rich in sensitized basophils (15, 16). SRS-A has not been detected 
in tissues (7)  or cells,  normal or sensitized,  as a  preformed chemical mediator;  and its 
release  in  vitro  occurs  more  slowly  than  that  of the  preformed  chemical  mediators, 
histamine and eosinophil chemotactic factor of anaphylaxis (ECF-A)  (7,  17),  consistent 
with a requirement for formation before release. 
Although  knowledge  of the  physicochemical  characteristics  of SRS-A  and  the 
immunoglobulins  and  critical  cell types responsible  for its release has evolved, 
there  has  been  no  demonstration  of  its  cellular  generation  before  release. 
Alteration  of  the  tissue  extraction  procedure  for  residual  mediators  by  the 
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institution  of  freeze-thawing  six  times  to  eliminate  boiling  or  acid  treatment 
revealed  the  accumulation  of  SRS-A  after  an  IgE-dependent  reaction  in  lung 
fragments  or isolated  lung  cells.  Thus,  it was  possible  for the  first time  to define 
the  time-course  of  the  intracellular  formation  of  SRS-A  which  precedes  its 
release. 
Materials and Methods 
Chymopapain, collagenase, and catalase (Worthington Biochemical Corp., Freehold, N. J.), elastase 
(Sigma  Chemical  Co.,  St.  Louis,  Mo.),  pronase,  deoxyribonuclease,  and  N6,O~dibutyryl  cyclic 
3',5'-adenosine  monophosphate  (dibutyryl  cyclic  AMP,  Calbiochem,  San  Diego,  Calif.),  gelatin 
(Difco Laboratories, Detroit, Mich.), sodium metrizoate (Triosil-75, Glaxo Laboratories, Ltd., Green- 
ford, England), sodium diatrizoate (Hypaque,  Winthrop Laboratories, New York), Ficoll (Pharmacia 
Fine  Chemicals,  Inc.,  Piscataway,  N.  J.),  silicic acid (100-200 mesh) and Amberlite XAD-2 (Mal- 
linekrodt Chemical  Works,  St.  Louis,  Mo.),  histamine acid  phosphate (Mann Research Labs,  Inc., 
New York),  atropine sulfate (Sigma Chemical Co.),  mepyramine maleate (Merck,  Sharp & Dohme, 
West  Point,  Pa.),  no.  80 brass sieve (Matheson Scientific, Inc.,  Stoneham,  Mass.),  8/~m pore-size 
micropore filters (Millipore Corp.,  Bedford, Mass.),  and five times recrystallized ovalbumin (Miles 
Laboratories,  Inc.,  Miles  Research  Div.,  Kankakee,  Ill.)  were  purchased  from  the  manufacturers. 
Ficoll-Hypaque cushions were made as described by BSyum (18).  Ragweed antigen E  (Research Re- 
sources  Branch,  NIAID,  Bethesda,  Md.),  and  8-bromo-cyclic  3',5'-guanosine  monophosphate  (8- 
bromo-cyelic GMP,  L.  Simon, ICN Nucleic Acid Research Institute, ICN Corp., Irvine, Calif.) were 
provided  as  noted.  All  solvents used  in silicic acid  chromatography of SRS-A were of nanograde 
quality. The atopic serum from a ragweed-sensitive patient (SAG) had a concentration of 250 ng IgE 
protein/ml by radioimmunodiffusion (19). Rabbit antihuman lgE,  provided by Dr. Peter H. Schur, 
Robert B. Brigham Hospital, Boston, Mass., was made against purified Shackford IgE myeloma (20), 
precipitated in 40% ammonium sulfate, and then subjected to immunoabsorption with normal human 
serum coupled to Sepharose 6B (21). The absorbed rabbit anti-IgE gave no precipitin lines on immuno- 
electrophoretic analysis with normal human serum. Tyrode's buffer (22) was used throughout unless 
otherwise noted. 
Mediator Bioassays.  The isolated atropinized guinea pig ileum was used to bioassay histamine, 
and the same preparation with the addition of an antihistamine was employed to quantitate SRS-A 
(10). Prostaglandin activity was assayed on the isolated ascending colon of the gerbil (23). ECF-A was 
assessed  by a  modification  (24)  of the Boyden chamber chemotactic technique (25)  with purified 
human eosinophils (26). 
SRS-A in diffusates or extracts of tissue or cells was characterized further by purification (1) of 
activity extracted into 80% ethanol. The extract was centrifuged at 19,000 g for 10 min at 4°C; and the 
supernate was flask evaporated, resuspended in distilled water, exposed to 0.1 N NaOH at 37°C for 30 
min, and applied to a  10 ml Amberlite XAD-2 column. After a water wash of 30 ml, the activity was 
eluted  with 30  ml  of 80%  ethanol,  flask evaporated,  resuspended  in  1.1  ml of 100% ethanol, and 
applied to a  10 ml silicic acid column. 30 ml of each of the following solvents were then applied in a 
stepwise  fashion:  hexane,  methylene  chloride,  acetone,  n-propanol,  and  ethanol:concentrated 
ammonia:water (in a 6:3:1 vol/vol ratio). Each 30-ml eluate was flask evaporated and suspended in 
Tyrode's buffer for bioassay. 
IgE-Dependent  Reactions  in  Human  Lung  Fragments  and  Cell Preparations.  Specimens  of 
grossly normal-appearing human lung were obtained from patients at the time of surgery for lung 
cancer.  The  lung  tissue  was  washed  and  fragmented  as  previously  described  (13).  Reversed 
anaphylactic  mediator release was  carried out with duplicate 250-  or 500-mg portions of replicate 
fragments incubated with a final dilution of 1:50 rabbit antihuman IgE in a vol of i ml at 37°C for the 
time  period  stated.  For  direct  anaphylactic  mediator  release  from  passively  sensitized  lung 
fragments, 250- or 500-mg replicates were sensitized in 1 ml of SAG serum diluted 1:3 for 18 h at room 
temperature, washed three times, and challenged at 37°C with 200 ng ragweed antigen E in a final vol 
of i  ml for the time stated. To terminate either direct or reversed release, the reaction mixtures were 
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tissues  were resuspended in 3 ml of Tyrode's buffer and freeze-thawed six times in a dry ice-acetone 
bath to disrupt the cells and recover the mediators for bioassay. 
The method of Gould et al. (27) to isolate rabbit lung cells was applied with minor modifications to 
human lung. Washed human lung fragments suspended  in Tyrode's buffer were exposed to 2.0 mg/ml 
pronase  and 0.5  mg/ml chymopapain for 20  rain  at 37°C with stirring.  Freed cells were separated 
from residual  fragments by sieving through a no. 80 brass fine wire-mesh sieve and were washed three 
times in Tyrode's buffer. The residual  fragments were treated with 1.0 mg/ml collagenase. 10.0 U/ml 
elastase,  0.03 mg/ml deoxyribonuclease,  and 0.1  mg/ml catalase for 20  min at 37°C  with stirring. 
Freed cells were again separated from the residual  fragments by sieving and washing, and the cells 
from both digestion  steps were combined and diluted to 107 nucleated cells/ml in Tyrode's solution 
made in 0.1 g/100 ml in gelatin (Tyrode's gelatin). 2.5 ml of cell suspension  were layered over 2.5 ml of 
FicolbHypaque and centrifuged at 400 g for 30 min at room temperature. Cells at the Tyrode's-Ficoll- 
Hypaque interface were aspirated with an 18-gauge needle, while cells in the pellet at the bottom of 
the tube were  obtained by resuspension  after the fluid layers  had been discarded.  Cells from the 
interface  were  identified  with  Wright's  stain  or  toluidine  blue  as  mast  cells,  macrophages, 
lymphocytes,  lung  parenchymal  cells,  and  lung  stromal  cells,  with  only  minor  erythrocyte 
contamination; these cells contained  more than  70% of the histamine and ECF-A in the starting 
mixture. Cells sedimenting to the bottom were predominantly erythrocytes and polymorphonuclear 
leukocytes  and contained less than 5% of the original histamine and ECF-A. Cells from the interface 
were resuspended  in Tyrode's gelatin and,  after three washes  to remove the Ficoll-Hypaque, were 
used  for  mediator release.  In  passive  sensitization experiments,  25  ×  106 cells  were incubated  in 
duplicate in a 1-ml vol of SAG serum diluted 1:3 at 37°C for 90 min, washed three times with Tyrode's 
gelatin,  and then challenged  with 200 ng of ragweed antigen E at 37°C for 30 min in a final vol of 1 ml 
Tyrode's gelatin unless  otherwise  noted. In reversed  anaphylactic mediator release,  25  ×  10 e cells 
were incubated in duplicate in 1 ml of rabbit antihuman IgE in a final dilution of 1:50 for the time 
indicated. In order to terminate the release  reactions,  the suspensions  were diluted to 3 ml by the 
addition  of  iced  Tyrode's  gelatin,  and  the  cells  were  sedimented  at  400  g  for  5  min  at  room 
temperature.  The supernates  were decanted  and  the cell  pellets resuspended  in 3 ml of Tyrode's 
gelatin and  freeze-thawed  in a dry  ice-acetone  bath  six  times.  Both  supernates  and  tissue  or  cell 
extracts were assayed  for the mediators of immediate hypersensitivity. The quantities of SRS-A in 
supernates and cell extracts were expressed  as units obtained from the cells freed from 10 g of lung 
tissue  (U/10 g lung equivalent). The number of lung cells freed and recovered  after Ficoll-Hypaque 
purification varied from  15 to 50  ×  106 cells/10 g of lung tissue with 4-8% being mast cells. 
Results 
SRS-A  Generation  and  Release.  The  knowledge  that  SRS-A  was  not  a 
preformed  mediator  but  yet  appeared  in  the  diffusate  within  minutes  after an 
immediate-type  hypersensitivity reaction in tissue  implied either a  brief period 
of  intracellular  residence,  extracellular  formation,  or  a  failure  of  existing 
methodologies  to  extract  SRS-A  in  its  tissue  phase,  The  previously employed 
techniques of boiling for  10  min in Tyrode's buffer with or without acidification 
(7)  as  well as  a  freeze-thawing procedure  adopted  for the  extraction of ECF-A 
(28)  were  used  to  seek  SRS-A in  normal  and  sensitized  lung  tissue  before and 
after challenge.  Sensitized tissues  exposed to specific antigen  not only released 
SRS-A  into  the  supernate  but  disclosed  tissue  SRS-A  with  extraction  by  the 
freeze-thawing technique.  Accordingly,  it  was  possible  to  examine  the  cellular 
generation of SRS-A before its release from human  lung tissue or isolated cells by 
direct and reversed anaphylactic  reactions. 
ACTIVATION BY ANTI-IgE.  The time-course of total SRS-A generation in human 
lung fragments,  as determined by the sum of the SRS-A remaining in the tissues 
and that released into the supernate after challenge of the tissues with anti-IgE is 1136  FORMATION  OF SRS-A IN HUMAN LUNG 
shown  in  Fig.  1.  SRS-A  was  undetectable  in  the  tissues  at  time  zero  and 
accumulated rapidly, reaching the maximum tissue level observed within 2 min 
after the addition of anti-IgE. In contrast, SRS-A release into the supernate was 
not  evident  until  2-5  min  and  proceeded to  increase  until  10  rain,  reflecting 
continued generation. Histamine release occurred within the 1st min and reached 
near maximum at 2 min, paralleling cellular SRS-A generation before release. 
Isolated cells  challenged with the  1:50  dilution of anti-IgE  (Fig. 2)  demon- 
strated an accumulation of cellular SRS-A at  1 min with a  plateau at 2 min. 
Release of SRS-A began concomitant with cellular accumulation and proceeded 
to rise  throughout the  30  min of observation,  implying continued generation. 
ECF-A and  histamine release  (not shown)  were  maximal at  2  min,  reaching, 
respectively, 34% and 18% net total release, and plateauing with cellular SRS-A 
at a time when SRS-A generation was continuing. In two additional experiments, 
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Fro. 1.  Time-course of generation and release of SRS-A from human lung fragments challenged with 
anti-IgE. Ill, SRS-A residual; r'q, SRS-A release; A, SRS-A total; and Q, histamine release. 
cellular  SRS-A  again  plateaued  at  approximately  2  min,  with  generation 
continuing as assessed by increasing release for 15-30  min. 
The failure to demonstrate the accumulation of SRS-A in cells before release 
by a  1:50  dilution of anti-IgE in  kinetic experiments prompted an alternative 
approach  in  which  the  intensity of the  reversed  anaphylactic activation was 
varied.  Isolated cells  challenged with a  1:1,000  or  1:2,000  dilution of anti-IgE 
accumulated SRS-A without release (Fig. 3). As the antibody concentration was 
increased to  1:100 or  1:200,  there  was  an approximately equal  distribution of 
SRS-A between cells and supernate, while with a 1:20 dilution of anti-IgE, all of 
the SRS-A detected was in the supernate. As the total SRS-A generated, the sum 
of  that  in  the  cells  and  supernate,  was  essentially the  same  with  antibody 
concentrations from 1:200 to 1:20, and approximately three times that in the cells 
activated with antibody concentrations of 1:1,000 or 1:2,000, it is evident that the 
intensity of activation influences both the total quantity of SRS-A generated and 
the percentage released at 30 min. R. A. LEWIS,  S. I. WASSERMAN,  E. J. GOETZL,  K. F. AUSTEN  1137 
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FIG. 3.  SRS-A  generation and release from isolated human lung cells challenged for 30 min by varying 
concentrations of anti-IgE. 
ACTIVATION BY IgE-ANTIGEN  INTERACTION.  The time-course of total SRS-A gen- 
eration in passively sensitized human lung fragments as determined by the sum 
of SRS-A  accumulated  in  the  tissue  and  that  released  into  the  diffusate  after 
antigen challenge is depicted in Fig. 4. SRS-A was undetectable in the sensitized 
tissues  at time zero,  but  accumulated rapidly after antigen  challenge,  reaching 
the  maximum  tissue  level  observed within  2  min.  On  the  other  hand,  SRS-A 1138  FORMATION  OF SRS-A  IN  HUMAN  LUNG 
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FIG. 4.  Time-course of SRS-A generation and release from passively sensitized human lung fragments 
challenged with antigen E. l,  SRS-A residual; El, SRS-A release; A, SRS-A total; and 0, histamine re- 
lease. 
release into the diffusate was not evident until 2-5 min after antigen challenge 
and increased over  15  min, reflecting continued generation. Histamine release 
began  within the  1st  min  and  reached  near  maximum at  2  min,  paralleling 
SRS-A generation before release. 
Isolated  passively  sensitized  lung  cells  challenged  with  specific  antigen 
resembled the whole tissue in demonstrating a lag time between the accumula- 
tion of SRS-A in cells and its release (Fig. 5). SRS-A was undetectable in the cells 
at time zero, but appeared rapidly, reaching the maximum level observed by 1 
rain. Release into the supernate was not evident until 5 min and increased until 
30  min,  reflecting continued generation.  Histamine release was maximal at 2 
rain, paralleling cellular SRS-A generation before release. 
In  order  to  examine  the  relationship  between  the  magnitude  of  passive 
sensitization as assessed by antigen-induced histamine release and the genera- 
tion of SRS-A, isolated lung cells were passively sensitized with varying doses of 
atopic serum  (Fig. 6)  and challenged with a  fixed dose of antigen. While cells 
interacted with dilutions of 1:4 and 1:2 of atopic serum released histamine upon 
antigen  challenge,  those  interacted  with  dilutions  of  1:16 and  1:8  did  not, 
implying that the lesser concentrations of IgE failed to sensitize the target cells. 
On  the  other  hand,  cells  interacted with  1:16 and  1:8  dilutions of antiserum 
accumulated SRS-A after antigen challenge in the absence of SRS-A release. 
Unsensitized and antigen-exposed cells did not contain SRS-A.  Thus,  as with 
reversed  anaphylactic challenge,  the  cellular accumulation of SRS-A  without 
release reflects a  minimal but definite immunologic activation. Sensitization at 
the greater concentrations of atopic serum followed by antigen challenge was not 
only  accompanied  by  release  of  SRS-A  into  the  supernate,  but  also  by  an 
incremental increase in total SRS-A generation. R.  A.  LEWIS,  S.  I.  WASSERMAN,  E.  J.  GOETZL,  K.  F.  AUSTEN  1139 
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Fro. 5.  Time-course of SRS-A generation and release from passively sensitized isolated human lung 
cells challenged with antigen E. I, SRS-A residual; El, SRS-A release; A, SRS-A total; and El, hista- 
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Fro. 6.  SRS-A generation and release from isolated human lung cells passively sensitized with varying 
concentrations of atopic serum and challenged with specific antigen. I, SRS-A residual; El, SRS-A re- 
lease; A, SRS-A total; and 0, histamine release. 
Partial Purification of Extracted and Released SRS-A.  In order to establish 
that the material extracted and released and designated as SRS-A by bioassay on 
the  atropinized  antihistamine-treated guinea  pig  ileum  did  indeed  represent 
SRS-A  activity,  partial  purification  (1)  was  carried  out  (Table  I).  In  this 1140  FORMATION  OF  SRS-A  IN  HUMAN  LUNG 
TABLE I 
Partial Purification  of SRS-A* 
Procedure 
Recovery of 
Recovery of 
supernatant  residual SRS-A 
SRS-A 
Starting material 
Ethanol extraction 
0.1 N NaOH (37°C × 30 min); Am- 
berlite XAD-2 chromatography 
Silicic acid chromatography: 
Hexane 
Methylene chloride 
Acetone 
n-Propanol 
Ethanol:concentrated  ammonia: 
water (6:3:1, vol/vol) 
U  U 
100  240 
75  225 
65  180 
<5  <5 
<5  <5 
<5  <5 
<5  <5 
35  i00 
*Generated from a  single 250-mg portion of passively sensitized human 
lung fragments 30 min after antigen challenge as described in the Mate- 
rials and Methods. 
procedure,  cleavage  of  phospholipids  is  accomplished  by  base  hydrolysis; 
histamine,  serotonin, and  the kinins are removed by their elution in the water 
wash  from Amberlite XAD-2;  and prostaglandins are extracted in hexane and 
acetone during silicic acid chromatography. SRS-A is stable to base hydrolysis, 
elutes in 80% ethanol on Amberlite XAD-2 chromatography, and remains on the 
silicic acid until the application of ethanol:concentrated ammonia:water (6:3:1). 
As shown in Table I, the recovery of SRS-A was 35 of 100 U in the initial super- 
nate and 100 of 240 U~in the initial extract of residual mediator. Although a 35- 
42%  recovery is  somewhat  less  than  that  observed when  1,000  times  as  much 
material  was  processed  (1),  it  is  completely  characteristic  of the  recoveries 
repeatedly  obtained  with  small-scale  purification.  A  similar  recovery  was 
observed for supernatant and cellular SRS-A recovered from tissues or isolated 
cells challenged with anti-IgE. 
Modulation  of  SRS-A  Generation  by  Action  of  Cyclic  Nucleotides.  The 
capacity to measure total SRS-A generation as the sum of that in the tissues and 
that  released  into  the  supernate  prompted  an  analysis  of the  effect of cyclic 
nucleotides upon the generation of SRS-A. It had previously been observed that 
the endogenous elevation of cyclic AMP or the addition of exogenous dibutyryl 
cyclic AMP inhibited SRS-A release (13, 29), while cholinergic stimulation or the 
introduction of 8-bromo-cyclic GMP  enhanced release  (19);  but  these  experi- 
ments did not distinguish an action on generation separate from release. Human 
lung fragments that were passively sensitized revealed no detectable SRS-A after 
2- or 30-min incubation in buffer, while antigen challenge resulted in generation 
of 30 U of SRS-A/g lung tissue at 2 min and 280 U/g at 30 min (Fig. 7). At 2 min, 
none of the SRS-A generated had been released into the fluid, while at 30 min, 
approximately 67% had been discharged. Preincubation of the fragments for 20 
min with 10 -3 M  dibutyryl cyclic AMP completely prevented SRS-A generation R.  A.  LEWIS,  S.  I.  WASSERMAN,  E.  J.  GOETZL,  K.  F.  AUSTEN  1141 
Fro. 7.  Cyclic nucleotide modulation of SRS-A generation from passively sensitized human lung frag- 
ments. 
at 2 and 30 min, in that no SRS-A was extractable from the tissue and none was 
found in the supernate. Preincubation of the fragments for 20 min with 10 _8 M 
8-bromo-cyclic GMP increased SRS-A generation at 2 min from 30 to 80 U and at 
30 min from 280 to 390 U. Despite the 2.5-fold increase in SRS-A generation at 2 
min, the product was entirely within the tissues, while at 30 min, 75% of that 
generated had been released. 
Discussion 
The capacity to extract SRS-A from human lung tissue or cells after immuno- 
logic  activation  and  the  measurement of SRS-A  in  both the  extract and the 
surrounding  fluid  permit  an  analysis of SRS-A  generation.  That  the  SRS-A 
extracted was not merely trapped in interstitial spaces after release was indicated 
by its detection not only within tissue (Figs. 1 and 4) but within isolated washed 
cells  after  activation  by  reversed  (Figs.  2  and  3)  or  direct  (Figs.  5  and  6) 
anaphylaxis. The propensity of SRS-A to adsorb to a variety of surfaces as well as 
to certain plasma proteins (4, 30) does not account for its extraction from cells, 
since thorough washing did not diminish its association with the cell fraction 
and,  more  importantly,  the  total  SRS-A  generated  did  not  bear  a  fixed 
relationship to the fraction remaining within the cells (Fig. 3).  Further, under 
three circumstances the SRS-A detected was entirely intracellular, implying that 
release had not yet occurred. These conditions included: the initial 1-2 min of 
SRS-A generation after activation by reversed anaphylaxis (Fig. 1)  in lung frag- 
ments and by direct anaphylaxis in passively sensitized lung fragments (Fig. 4) 
and isolated cells (Fig. 5); the response of isolated cells to limited immunologic 
activation as achieved by challenge with low doses of anti-IgE (Fig. 3) or passive 
sensitization with low concentrations of atopic serum before antigen challenge 
(Fig.  6);  and  the  action  of exogenous  8-bromo-cyclic  GMP  which  yielded a 1142  FORMATION  OF  SRS-A  IN  HUMAN  LUNG 
2.5-fold increase in the quantity of SRS-A generation without release at 2 min in 
passively sensitized antigen-challenged lung fragments (Fig. 7). 
That  the  material  extracted  was  indeed  SRS-A  was  established  by  both 
differential  bioassay  and  purification.  Both  the  tissue  and  cell  extract  and 
supernatant  SRS-A  failed  to  contract  the  isolated  gerbil  colon  (23) at  a 
concentration five times that yielding a  1 U response on the isolated guinea pig 
ileum  pretreated  with atropine and  antihistamine. During purification of the 
ethanol  extract  of tissues,  cells,  or  diffusates,  all  contractile  activity for the 
isolated atropinized antihistamine-treated guinea pig ileum eluted with ethanol 
from Amberlite XAD-2 and not with distilled water. Further, during silicic acid 
chromatography, no activity appeared with solvents capable of eluting prosta- 
glandins,  and  recovery  was  limited  to  the  solvent  previously  established  as 
selectively eluting SRS-A (1). 
The quantitation of SRS-A in tissues and cells as well as in the surrounding 
medium introduces an additional dimension to the study of SRS-A generation 
and  may  well  clarify  certain  previously  recognized  differences  between  the 
elaboration of this mediator and those known to be preformed. The capacity of 
certain  pharmacologic agents such  as  diisopropyl fluorophosphate (DFP)  (31), 
isoproterenol in the presence of carbamylcholine (32),  and the cytochalasins A 
and  B  (33) to  suppress  SRS-A  release  without  affecting or  even  enhancing 
histamine  release  may well  be  explicable  by  an  action  or  formation with  or 
without an additional effect on release. Treatment of lung fragments with DFP 
(31)  followed  3-5  min  later  by  washing  and  antigen  challenge  permitted 
histamine  release  may  well  be  explicable  by  an  action  or  formation with  or 
release if antigen challenge was carried out in the presence of DFP. Thus, the 
release of histamine requires the activation of an esterase from its DFP-resistant 
precursor form (34). In contrast, removal of DFP before antigen challenge did not 
relieve  the  inhibitory  effect  on  SRS-A  release  (31, 34),  implying  that  its 
generation involves an already active esterase. Stimulation of lung tissue with a 
fixed dose of isoproterenol sufficient to give a 10-fold increase in total tissue cyclic 
AMP completely prevented the subsequent appearance of histamine and SRS-A 
in  the diffusate after antigen challenge. The treatment of replicate fragments 
with increasing doses of the cholinomimetic agent carbamylcholine progressively 
reversed  the  inhibition of histamine release  and,  at the  highest dose,  yielded 
enhancement.  In  contrast,  there was  little  diminution of the  isoproterenol-in- 
duced rise in total tissue cyclic AMP and no reversal of the total suppression of 
SRS-A release  (32).  In view of the suppression of SRS-A  generation by cyclic 
AMP  (Fig.  7),  it  may well  be  that the  capacity of cholinergic stimulation to 
reverse adrenergic effects is more readily observed upon the secretory phase of 
mediator  release  than  upon  the  generation  of  SRS-A.  Similarly,  the  cyto- 
chalasins A and B, with an apparent site of action distinctly different from DFP 
or  the  cyclic  nucleotides,  suppressed  the  release  of SRS-A  at  concentrations 
which  fully  permitted  or  even  facilitated histamine  release  (33).  As  in  each 
instance it  is  SRS-A  release  that fails to occur in  association with histamine 
release, the observations could be unified by preferential action of the agents on 
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Another finding was that the intensity of the immunologic stimulus appeared 
to  determine both  the  quantity of the  SRS-A  generated  and  its  distribution 
between the cells and the fluid phase. Indeed, the presence of cellular SRS-A was 
a  more  sensitive  index  of  immunologic  activation than  its  detection  in  the 
surrounding fluid.  Challenge  of unsensitized cells  with low  concentrations of 
anti-IgE (Fig. 3) or sensitization with low concentrations of atopic serum followed 
by  antigen challenge  (Fig.  6)  resulted in  the  accumulation of cellular SRS-A 
without release.  Antigen-induced SRS-A formation in lung cells was observed 
without either histamine or SRS-A release (Fig. 6). Although the possibility of a 
preferential inactivation of mediators after release cannot be excluded, there is 
no evidence to support such an interpretation. As the intensity of the immuno- 
logic activation increased, there was not only a progressive shift of the detectable 
SRS-A to the surrounding medium, but also an increased generation (Figs. 3 and 
6). 
An additional consideration in the study of SRS-A generation relates to the 
possibility of more  than one intracellular source or more than one cell source, 
either by primary immunologic activation or secondary to the action of a primary 
chemical mediator on a second cell. Such a possibility is introduced because of 
the continued generation of SRS-A at a time when the tissue (Figs. 1 and 4)  or 
cellular  (Figs.  2  and  5)  content  has  plateaued  and  the  release  of preformed 
mediators is complete. The release of platelet-activating factor is an example of a 
primary mediator recruiting additional mediators through an effect on a second 
cell (35).  The release of SRS-A from the rat peritoneal cavity by both IgE and 
mast cell-dependent (36) and IgGa, complement, and polymorphonuclear leuko- 
cyte-dependent (37)  mechanisms illustrates that  more  than one cell type can 
participate in its generation. Another alternative is that the IgE immunoglobu- 
lins  bound  to  mast  cells  or  basophils  in  excess  of those required  for optimal 
release of preformed mediators interact with antigen to perturbate the membrane 
with resultant SRS-A generation independent of intracellular accumulation or of 
the discharge of preformed mediators. 
Summary 
The capacity to extract slow-reacting substance of anaphylaxis (SRS-A)  from 
human  lung  tissue  or  cells  after  immunologic  activation,  together  with  the 
measurement of SRS-A in both the extract and the surrounding fluid, permits 
study  of total  SRS-A  generation.  That  the  material  extracted  is  SRS-A  was 
established by both differential bioassay and purification. SRS-A accumulation 
was  entirely intracellular after limited IgE-dependent direct or  reversed ana- 
phylactic  activation.  Intracellular  accumulation  also  generally  preceded  re- 
lease, with generation of SRS-A continuing well beyond a plateau in the cellular 
SRS-A level and the  release  of preformed mediators. The quantity of SRS-A 
generated after immunologic activation was  modulated by the introduction of 
exogenous cyclic nucleotides, revealing a site of cyclic nucleotide action distinct 
from that on mediator release. The capacity to determine not only the release of 
preformed mediators but  also the generation of a  newly formed mediator, the 1144  FORMATION OF SRS-A IN HUMAN LUNG 
sum of SRS-A in cells and supernate,  adds an additional dimension to the anal- 
ysis of the cellular events of immediate hypersensitivity. 
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